| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 118, 1246-1248, Copyright © 1986 by Endocrine Society
ARTICLES |
GS Tannenbaum, M van der Rest, TR Downs and LA Frohman
The existence of discordant results regarding the effects of intracerebroventricular (icv) administration of GRF on GH secretion prompted a reexamination of the central actions of GRF and a detailed chemical characterization of the peptide designated as hpGRF-44-NH2. The icv injection of 10 micrograms rat (r) GRF to freely-moving rats caused an acute stimulation of GH release, whereas 10 micrograms of the putative hpGRF peptide icv continued to suppress spontaneous GH secretion. Through a series of biochemical and immunologic studies we demonstrate that peptide hpGRF-44-NH2, code number 92-81-5G-41-47, is predominantly ovine (o) CRF and also contains a small amount (3-5%) human (h) GRF-44-NH2. We conclude that the major effect of icv administered GRF, at high doses, is to stimulate GH release and that the central actions previously attributed to the hpGRF peptide are, in fact, due to the oCRF component of this compound.
This article has been cited by other articles:
![]() |
E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. TANNENBAUM Response: Effects of Growth Hormone-Releasing Factor in the Brain Science, June 6, 1986; 232(4755): 1272 - 1273. [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |